Vaxart (OTCMKTS:VXRT) Share Price Passes Below 200-Day Moving Average – Here’s What Happened

Vaxart, Inc. (OTCMKTS:VXRT)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.58 and traded as low as $0.58. Vaxart shares last traded at $0.6001, with a volume of 682,120 shares traded.

Vaxart Stock Performance

The business has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.59. The firm has a market cap of $150.06 million, a price-to-earnings ratio of 4.13 and a beta of 1.10.

Vaxart (OTCMKTS:VXRT) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The firm had revenue of $39.23 million during the quarter, compared to the consensus estimate of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Institutional Trading of Vaxart

Several institutional investors have recently made changes to their positions in VXRT. Goldman Sachs Group Inc. bought a new position in shares of Vaxart during the first quarter valued at about $31,000. Creative Planning purchased a new stake in Vaxart in the 2nd quarter valued at about $33,000. Invesco Ltd. lifted its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.